Status:
COMPLETED
The Role of SNP rs2910164 in Patients Treated With Immune Checkpoint Inhibitors
Lead Sponsor:
University of Freiburg
Conditions:
Cancer
Eligibility:
All Genders
18-99 years
Brief Summary
The objective of this study is to investigate whether the SNP rs2910164 in the pre-miR-146a gene is associated with outcome and toxicity of immune checkpoint inhibitor therapy.
Detailed Description
The single nucleotide polymorphism (SNP) rs2910164 within the gene for microRNA-146a (miR-146a) reduces miR-146a expression. Previous studies of the investigators demonstrated that this SNP was associ...
Eligibility Criteria
Inclusion
- confirmed diagnosis of cancer
- treatment with an immune checkpoint inhibitor (anti-PD-1, anti-PD-L1 or anti-CTLA4)
- age ≥ 18 years
- peripheral blood sample available
- written informed consent
- ability to understand the nature of the study and the study related procedures and to comply with them
Exclusion
- age \< 18 years
- lack of informed consent
Key Trial Info
Start Date :
July 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2020
Estimated Enrollment :
179 Patients enrolled
Trial Details
Trial ID
NCT04038996
Start Date
July 1 2016
End Date
February 1 2020
Last Update
August 7 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.